Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

229 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas-an ENITEC Group Initiative.
Cuppens T, Annibali D, Coosemans A, Trovik J, Ter Haar N, Colas E, Garcia-Jimenez A, Van de Vijver K, Kruitwagen RP, Brinkhuis M, Zikan M, Dundr P, Huvila J, Carpén O, Haybaeck J, Moinfar F, Salvesen HB, Stukan M, Mestdagh C, Zweemer RP, Massuger LF, Mallmann MR, Wardelmann E, Mints M, Verbist G, Thomas D, Gommé E, Hermans E, Moerman P, Bosse T, Amant F. Cuppens T, et al. Among authors: salvesen hb. Clin Cancer Res. 2017 Mar 1;23(5):1274-1285. doi: 10.1158/1078-0432.CCR-16-2149. Clin Cancer Res. 2017. PMID: 28232476
High phospho-Stathmin(Serine38) expression identifies aggressive endometrial cancer and suggests an association with PI3K inhibition.
Wik E, Birkeland E, Trovik J, Werner HM, Hoivik EA, Mjos S, Krakstad C, Kusonmano K, Mauland K, Stefansson IM, Holst F, Petersen K, Oyan AM, Simon R, Kalland KH, Ricketts W, Akslen LA, Salvesen HB. Wik E, et al. Among authors: salvesen hb. Clin Cancer Res. 2013 May 1;19(9):2331-41. doi: 10.1158/1078-0432.CCR-12-3413. Epub 2013 Mar 28. Clin Cancer Res. 2013. PMID: 23538402
L1CAM expression in endometrial carcinomas: an ENITEC collaboration study.
van der Putten LJ, Visser NC, van de Vijver K, Santacana M, Bronsert P, Bulten J, Hirschfeld M, Colas E, Gil-Moreno A, Garcia A, Mancebo G, Alameda F, Trovik J, Kopperud RK, Huvila J, Schrauwen S, Koskas M, Walker F, Weinberger V, Minar L, Jandakova E, Snijders MP, van den Berg-van Erp S, Matias-Guiu X, Salvesen HB, Amant F, Massuger LF, Pijnenborg JM. van der Putten LJ, et al. Among authors: salvesen hb. Br J Cancer. 2016 Sep 6;115(6):716-24. doi: 10.1038/bjc.2016.235. Epub 2016 Aug 9. Br J Cancer. 2016. PMID: 27505134 Free PMC article.
PIK3CA Amplification Associates with Aggressive Phenotype but Not Markers of AKT-MTOR Signaling in Endometrial Carcinoma.
Holst F, Werner HMJ, Mjøs S, Hoivik EA, Kusonmano K, Wik E, Berg A, Birkeland E, Gibson WJ, Halle MK, Trovik J, Cherniack AD, Kalland KH, Mills GB, Singer CF, Krakstad C, Beroukhim R, Salvesen HB. Holst F, et al. Among authors: salvesen hb. Clin Cancer Res. 2019 Jan 1;25(1):334-345. doi: 10.1158/1078-0432.CCR-18-0452. Epub 2018 Nov 15. Clin Cancer Res. 2019. PMID: 30442683 Free PMC article.
229 results